Nephrology
Renal Disease
0
Pipeline Programs↗
2
Active Trials↗
4
Companies Involved↗
Renal Disease is an early-stage landscape with 0 programs across 4 companies. The most active players are La Jolla Pharmaceutical Company, Sanofi, Boehringer Ingelheim.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
14
clinical trials
Completed9 · 64%
Terminated2 · 14%
Recruiting1 · 7%
Unknown status1 · 7%
Active, not recruiting1 · 7%
Clinical Trials
Trial Activity
14 trials
Canagliflozin in Advanced Renal Disease With MRI Endpoints
Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT06182839·92 enrolled
The Modification of Diet in Renal Disease Study
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT04364113·840 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)